25842-31-3

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Benzylpiperidino)acetonitrile serves as an essential building block in the synthesis of pharmaceutical compounds, leveraging its chemical reactivity to create a variety of medicinal agents. Its cyclohexane ring structure and benzyl group contribute to the compound's ability to interact with biological targets, making it a valuable component in drug development.
Used in Scientific Research:
In the realm of scientific research, 2-(4-Benzylpiperidino)acetonitrile is utilized as a research chemical to study its properties and potential applications. Its unique structure allows researchers to investigate its interactions with various biological systems and to explore its use in the development of new therapeutic agents.
While the specific applications of 2-(4-Benzylpiperidino)acetonitrile in different industries are not explicitly detailed in the provided materials, its role in the pharmaceutical industry and scientific research is clear. Further investigation is necessary to fully understand its potential uses and to define its properties for safe and effective application in various fields.

InChI:InChI=1/C14H18N2/c15-8-11-16-9-6-14(7-10-16)12-13-4-2-1-3-5-13/h1-5,14H,6-7,9-12H2

Upstream product

• 31252-42-3 4-benzylpyperidine 
• 590-17-0 cyanomethyl bromide 
• 107-14-2 chloroacetonitrile 

Downstream Products

• 25842-32-4 1-(2-aminoethyl)-4-benzylpiperidine 
• 100221-96-3 N-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-2-chloro-benzamide 
• 100221-95-2 N-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-2-bromo-benzamide 
• 100221-98-5 N-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-benzamide 
• 100221-97-4 N-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-2-methyl-benzamide 

Relevant academic research and scientific papers

Novel Sigma Receptor Ligand-Nitric Oxide Photodonors: Molecular Hybrids for Double-Targeted Antiproliferative Effect

This contribution reports the synthesis and evaluation of novel hybrid compounds that conjugate a sigma (σ) receptor pharmacophore and a nitric oxide (NO) photodonor. All compounds preserve their capability to generate NO under visible light and possess overall σ receptor nanomolar affinity, with one of them (8b) exhibiting remarkable σ2 receptor selectivity. Compounds 8b, 11a, and 11b were tested on tumorigenic MCF-7 and A2058 cells expressing high levels of σ2 and σ1 receptor, respectively. Considerable loss of cell viability was detected under light excitation, while negligible effects in the dark were detected. Moreover, they did not show any significant cytotoxicity in the dark or under irradiation on nontumorigenic NCTC-2544 keratinocytes. NO-induced reduction of cellular viability was demonstrated by in-cell NO detection and total nitrite estimation. For the first time, a combination of σ receptor moieties and a NO photodonor is reported, providing distinctive ligands potentially useful for cancer management.

Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease

Development of Multi-Target Directed Ligands (MTDLs) has emerged as a promising approach for targeting complex etiology of Alzheimer's disease (AD). Following this approach, a new series of N′-(4-benzylpiperidin-/piperazin-/benzhydrylpiperazin-1-yl)alkylamine derivatives were designed, synthesized and biologically evaluated as inhibitors of cholinesterases (ChEs), amyloid-beta (Aβ) self aggregation and also for their radical scavenging activity. The in vitro studies showed that the majority of synthesized derivatives strongly inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values in the low-nanomolar range, and were clearly more potent than the reference compound donepezil in this regard. Among them, inhibitors 5h and 5k, strongly inhibited AChE, with IC50 value of 6.83 nM and 2.13 nM, respectively, and particularly, compound 5k was found to be highly selective for AChE (～38-fold). Moreover, both kinetic analysis of AChE inhibition and the docking study suggested that 5k binds simultaneously to catalytic active site and peripheral anionic site of AChE. Besides, these compounds also exhibited greater ability to inhibit self-induced Aβ1-42 aggregation at 25 μM with percentage inhibition from ～54% to 89% and specially compound 5k provided highest inhibition (88.81%). Also, the derivatives containing methoxy and hydroxy groups showed potent oxygen radical absorbance capacity (ORAC) ranging from 2.2- to 4.4-fold of the Trolox value. Furthermore, results of ADMET studies suggested that all compounds exhibited appropriate drug like properties. Taken together, these results suggest that 5k might be a promising lead compound for further AD drug development.

A Novel Cleavage Technique to Generate Small Molecule Compounds and Libraries via a Two-Resin System

Application of organic synthesis to solid supports has led to the successful implementation of combinatorial chemistry in the drug discovery process. This paper describes a novel use of the Hofmann elimination of tetrasubstituted amine salts on solid-phas

Synthesis, biological evaluation, and quantitative structure. A new class of potent H1 antagonists

Some [β-(Aroylamino)ethyl]piperazines and -piperidines and [2-[(Arylamino)carbonyl]ethyl]piperazines, -piperidines, -pyrazinopyridoindoles, and -pyrazinoisoquinolines have been synthesized and their H1-antagonistic activity studied in isolated guinea pig